



Cairo University

Faculty of Veterinary Medicine

Department of Surgery, Anesthesiology and Radiology

Simvastatin as a Growth Promoting Material on the Healing of Critical Sized Bone Defect in Dogs

(An Experimental Study)

Thesis presented by

Amani Magdi Nagi Mahmoud

(B.V.Sc., Assuit University, 2012)

For the degree of

M.V.Sc.

(Surgery, Anesthesiology and Radiology)

Under Supervision of

Prof. Dr. Mohamed Ayad Abdel Hamid

Prof. of Surgery, Anesthesiology and Radiology
Faculty of Veterinary Medicine
Cairo University

Dr. Elham A. Hassan

Lecturer of Surgery, Anesthesiology and Radiology
Faculty of Veterinary Medicine
Cairo University

Prof. Dr. Iman Bakr Shaheed

Prof. of Pathology and Vice Dean of Postgraduate
and Research
Faculty of Veterinary Medicine
Cairo University

2015



Cairo University
Faculty of Veterinary Medicine
Department of Surgery, Anesthesiology and Radiology

Supervision sheet

Prof. Dr. Mohamed Ayad Abdel Hamid

Professor of Surgery, Anesthesiology and Radiology
Faculty of Veterinary Medicine
Cairo University

Dr. Elham A. Hassan

Lecturer of Surgery, Anesthesiology and Radiology
Faculty of Veterinary Medicine
Cairo University

Prof. Dr. Iman Bakr Shaheed

Professor of Pathology and Vice Dean of Postgraduate and Research
Faculty of Veterinary Medicine
Cairo University



Cairo University

Faculty of Veterinary Medicine

Department of Surgery, Anesthesiology and Radiology

Name: Amani Magdi Nagi Mahmoud.

Nationality: Egyptian.

Date of birth: 21/10/1990.

Place of birth: El-Minia.

Specification: surgery, Anesthesiology and Radiography.

Degree: M.V.Sc.

Title of thesis:

" Simvastatin as a growth promoting material on the healing of critical sized bone defect in dogs".

Under Supervision of:

-Prof. Dr. Mohamed Abdel Hamid Ayad

Professor of Surgery, Anesthesiology and Radiology, Faculty of Veterinary medicine, Cairo University.

-Dr. Elham A. Hassan

Lecturer of Surgery, Anesthesiology and Radiology, Faculty of Veterinary medicine, Cairo University.

-Prof. Dr. Iman Bakr Shaheed

Professor of Pathology and Vice Dean of Postgraduate and Research, Faculty of Veterinary medicine, Cairo University.

Key words: Critical sized bone defect, Simvastatin, healing, dogs, osteopontin, Alizarine, Masson Trichrome.

Abstract

Critical size defect represents a major challenge in orthopedic surgery. The aim of the work was decided to study the effect of locally applied simvastatin as a growth promoting material on the healing of experimentally induced critical size bone defect in dogs.

A prospective experimental study was done on 18 skeletally mature male mongrel dogs. A 21 mm mid-shaft femoral defect was induced in all dogs. Dogs were randomly allocated into one of the two groups; group 1:- simvastatin was locally applied into the defect site, group 2:- defects were kept without simvastatin (sham-operated group). All defect sites were stabilized using bone plate and screws. Dogs were evaluated clinically and radiographically every two weeks till 12 weeks. The dogs were euthanized at 4,8 and 12 weeks for gross pathologic and histopathologic examination (Hematoxyline & Eosin, Masson Trichrome, Alizarine red and immune histochemical evaluation (osteopontin).

Simvastatin resulted in acceleration of bone healing on the induced critical size defect, the defects healed in a consistent pattern of consolidation, incorporation and remodeling . the femoral cortex opposite the bone plate demonstrated most mature remodeling, evident both radiographically as well as hitopathologically.

Local application of simvastatin may be advised for acceleration of bone healing in critical bone defects otherwise the empty critical defect resulted in an atrophic nonunion.

"DEDICATION"

To my parents.

To my siblings

Amani M. Nagi

Amani M. Nagi

Acknowledgments

*First and foremost, I thank **ALLAH** for giving strength to complete my young dream and for giving me happiness to finish the work,*

I thank my beautiful mother, because making her proud is still the reason I get out of bed in the morning. Her wisdom, strength, and a remarkable woman, are the reason I am able to do what I do.

*I'd like to express the deepest appreciation to **Prof. Dr. Mohamed Ayad Abdel Hamid** Prof. of Surgery, Anesthesiology and Radiology, Fac. Vet. Cairo University, for his supervision, encouragement and unlimited support throughout the study.*

*I'd like to thank the precious doctor that I have ever met **Dr. Elham A. Hassan** Lecturer of Surgery, Anesthesiology and Radiology, Fac. Vet. Cairo University, for her supervision, magnificent help and encouragement throughout the study.*

*I would like to express my great feeling of appreciation toward **Prof. Dr. Iman Bakr Shaheed** Prof. of Pathology and Vice Dean of Postgraduate and Research, Fac. Vet. Cairo University, for her help in the interpretation of the histopathological study.*

Many thanks for the support that presented by all staff members, colleagues, technicians and assistants in Surgery, Anesthesiology and Radiology Department, Faculty of Veterinary Medicine, Cairo University.

Contents

I-INTRODUCTION.....	1
II- REVIEW OF LITERATURE	
Bone formation	3
Normal vascularization of bone.....	4
Innervation of the bone.....	5
Bone fracture.....	5
Stages of bone healing.....	9
Assessment of fracture healing.....	13
Simvastatin.....	14
The pleotropic effects of simvastatin.....	16
Potential role of simvastatin on bone regeneration.....	17
Effect of the route of administration on simvastatin action.....	18
Dose adjustment.....	20
Observational/ clinical and experimental implication of simvastatin.....	22
III-MATERIALS AND METHODS.....	24
IV- RESULTS.....	36
V- DISCUSSION.....	70
VI- CONCLUSION.....	83
VII- SUMMARY.....	84
VIII- REFRNCES.....	86
Arabic summary	

List of abbreviations

Abbreviation	Denote
ALP	Alkaline phosphatase
BMD	Bone mineral density
BMPs	Bone morphogenetic proteins
Cbfa 1	Core- binding factor 1
Cm	Centimeter
CPR	C- reactive protein
Cyr 61	Cysteine- rich 61
DCP	Dynamic compression plate
DJD	Degenerative joint disease
DNA	Dinucleic Acid
ECs	Endothelial cells
EDTA	Ethylene diamine tetra-acetic acid
eNOS	Endothelial nitrous oxide synthesase
FFD	Focal film distance
FGFs	Fibroblast growth factors
G	Gauge
H&E	Hematoxyline & Eosin
HMG-CoA	Hydroxymethylglutaryl- CoA
I.M.	Intramuscular
I.V.	Intravenous
IACUC	Institutional Animal Care and Use Committee
IGF	Insulin- like growth factors
IL	Interleukin
iNOS	Inducible nitrous oxide synthesase
Kg	Kilogram
kVp	Kilo voltage
LDL	Low-density lipoproteins
LPS	Lipo-poly saccharide

mAs	Milliampair second
Max	Maximum
MCP-1	Monocyte chemotactic protein-1
Mg	Milligram
Min	Minimum
Mm	Millimeter
MMP-9	Matrix metalloproteinase-9
mRNA	messenger Ribonucleic acid
MSCs	Mesenchymal stem cells
MTC	Masson Trichrome
NO	Nitric oxide
NRS	Numerical Rating Scale
OPG	Osteoprotegerin
PDGF	Platelet-derived growth factor
RANK	Receptor activator of nuclear factor kappa β
RANKL	Receptor activator of nuclear factor kappa β ligand
S	Second
SD	Standard deviation
SIM	Simvastatin
TCP	Tricalcium phosphates
TGF- β	Transforming growth factor- β
TNF- α	Tumor necrosis factor- α
VEGFs	Vascular endothelial growth factors

List of tables

Table	Title	Page
Table (1)	Rate of union in terms of clinical union using bone plate in dogs	12
Table (2)	Numerical rating scale (NRS) for assessing the severity of clinical signs of lameness in dogs	33
Table (3)	Ordinal scale used for evaluation radiographs	34
Table (4)	Histomorphological classification for staging bone consolidation	35
Table (5)	Mean \pm SD and range of pelvic limb lameness score using numerical rating score (NRS) for both simvastatin group and control group.	38
Table (6)	Mean \pm SD of radiographic assessment score of the defect site in simvastatin and control group throughout the study.	44
Table (7)	Mean of RGB to grades of step wedge using Photoshop® software	46
Table (8)	Mean of RGB at different time (4,8,12 weeks) using Photoshop® software	46
Table (9)	Correlation between clinical, radiographical and histopathological in simvastatin group	67

List of figures

Figure	Title	Page
Fig.(1)	Topographical distribution of diseases of the canine appendicular musculoskeletal system.	5
Fig.(2)	Distribution of major diseases categories of the canine appendicular musculoskeletal system	6
Fig.(3)	Molecular structure of simvastatin	15
Fig.(4)	The interaction between HMG-CoA reductase inhibitors in the mevalonate pathway	16
Fig.(5)	Diagram showing the grouping of the animals	25
Fig.(6)	a. lateral approach to the hind limb after prepared for surgery; b. Skin incision was made along the length of the femur.	28
Fig.(7)	a. Dissection of subcutaneous tissue till exposure of tensor fascia lata muscle; b. Incision that was made in tensor fascia-lata muscle using blunt ends scissor to exposure of the underlying muscle.	28
Fig.(8)	a. Retraction of vastus lateralis muscle and biceps femoris muscle cranially and caudally till exposure of femur bone; b. Dilation of the site by wound dilator and holding/ elevated of the femur by Hohmann.	29
Fig.(9)	a. Dissection/ loosening of the muscle that attached to the femur and elevation of the periosteum from the site of defect was performed; b. Alignment of the plate using plate blinder to be closely attached to the bone.	29
Fig.(10)	a. Fixation of the plate after the alignment to adjust the femur contour by using bone forceps; b. Detection of defect length using sterilized metal ruler and marked the defect size.	30
Fig.(11)	a. Holing the plate's holes before using screws to fix the plate by using drill; b. Taping after drilling the hole before tying screws.	30
Fig.(12)	a. Fixation of the plate (Dynamic compression plate) on the femur was fixed by using self-taping screws; b. The defect was done by using bone saw which was 2.1 cm.	31
Fig.(13)	a. The defect which was performed was removed or distracted; b. Insertion of simvastatin in the site of the defect bone.	31
Fig.(14)	a and b. closure of the muscle by continuous suture using catgut; c. Suture of the subcutaneous tissue; d. Suture of the skin by simple interrupted using silk.	32
Fig.(15)	Standing weight bearing on operated limbs in simvastatin group. a: non-weight bearing during first week. b: Supporting weight bearing from the 6th to 10th week. c: complete weight bearing at the 12th week.	37
Fig.(16)	Mean \pm SD of Simvastatin and control group of pelvic limb lameness score using numerical rating score (NRS) throughout the	38

	study.	
Fig.(17)	Cranio-caudal Radiographs of the right femur of the dog (immediately, 4, 8 and 12 weeks) post-operatively in simvastatin group. The defect site was gradually decreased.	39
Fig.(18)	Cranio-caudal radiographic view of the right femur after 2 weeks demonstrating large callus formation proximal and distal to the defect site.	40
Fig.(19)	Cranio-caudal radiographs of the right femur (immediately, 4,8 and 12 weeks) post-operatively in control group. The defect site doesn't change in size and at the 12 week osteolysis was happen in the fracture line.	41
Fig.(20)	Cranio-caudal view of x-ray film on the femur demonstrating bending of the plate by the 2nd week in segmented defect.	42
Fig.(21)	Mean \pm SD of radiographic assessment of the defect site in simvastatin and control group throughout the study.	44
Fig.(22)	Contact radiographs to the right femur bone at (4, 8 and 12 weeks) after euthanization using the Digimizer® software to measure the length of the defect medial and lateral to cortex of the femur.	45
Fig.(23)	Histogram to step wedge using Digimizer® software.	47
Fig.(24)	Histogram to contact x-ray femur bone at 4 weeks with step wedge using Digimizer® software.	47
Fig.(25)	Histogram to contact x-ray femur bone at 8 weeks with step wedge using Digimizer® software.	48
Fig.(26)	Histogram to contact x-ray femur bone at 12 weeks with step wedge using Digimizer® software.	48
Fig.(27)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks following surgery showing massive inflammatory cells infiltration with newly formed blood capillaries (arrows) were seen in between the inflammatory cells at the proximal bone defect site. (H&E), X100 .	50
Fig.(28)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks following surgery demonstrating large area of immature fibrous tissue (arrows) at the proximal defect site notice newly blood capillaries and few numbers of inflammatory cells. (H&E), X100 .	50
Fig.(29)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery showing mature fibrous tissue (arrows) with considerable number of young osteoblasts in between bone trabeculae. Mononuclear cell infiltration were seen in some sections. (H&E), X100 .	51
Fig.(30)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery. Mature fibrous tissue with uniform integration of the bone with presence of more organized	51

	anastomosing newly formed bone trabeculae (arrows) at the defect site. (H&E), X100.	
Fig.(31)	Higher magnification of previous photo showing fibroblast cells (arrows), fibrin threads mixed with immature collagen and mononuclear cell infiltration(H&E). X400.	52
Fig.(32)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery showing mature collagen arranged in normal pattern with blood capillaries (arrows) (H&E). X100.	52
Fig.(33)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery demonstrating newly formed blood capillaries (arrows) with marked osteoblastic activity(H&E). X100.	53
Fig.(34)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery showing mature fibrous tissue (arrows) (H&E). X100.	53
Fig.(35)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery demonstrating large number of active osteoblast cells with less inflammatory cell infiltration (arrows) and bundles of mature fibrous tissue(H&E). X100.	54
Fig.(36)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks following surgery demonstrating large number of active osteoblast cells (arrows)(H&E). X400.	54
Fig.(37)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks following surgery showing extensive area of new bone formation occupying the defect site (arrows) and moderate lamellar bone with active mature osteoblast cells filling the defect site with no evidence of osteoclast cells (H&E). X100.	55
Fig.(38)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks following surgery demonstrating large number of active osteoblast cells without evidence of the presence of osteoclast and the presence of moderate lamellar bone formation (arrows) and newly formed blood vessels (H&E). X100.	55
Fig.(39)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks stained with MTC, demonstrating large area of immature fibrous tissue with immature collagen threads (arrows) adjacent to the marrow cavity at the proximal defect site, X100.	56
Fig.(40)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks stained with MTC. A large area of light bluish immature collagen threads (arrows) at the proximal defect site, X100.	57
Fig.(41)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks stained with MTC. A large area of light bluish immature collagen threads (arrows) at the distal defect site, X100.	57
Fig.(42)	Photomicrograph of the proximal part of the newly formed callus in simvastatin group at 8 weeks stained with MTC. A more organized	58

	mature collagen threads (arrows) with newly formed blood vessels were occupying the defect site, X100.	
Fig.(43)	Photomicrograph of the distal part of the newly formed callus in simvastatin group at 8 weeks stained with MTC. A more organized mature collagen threads (arrows) were occupying the defect site, X100.	58
Fig.(44)	Photomicrograph of the bone defect site in the proximal part of newly formed callus in simvastatin group at 8 weeks stained with MTC. A mature collagen threads were occupying the defect site in small number with a large number of active osteoblast cells and neovascularization (arrows) were demonstrated, X100.	59
Fig.(45)	Photomicrograph of the bone defect site in the distal part of the newly formed callus in simvastatin group at 8 weeks stained with MTC. A mature collagen threads (arrows) were occupying the defect site in small number with a large number of active osteoblast cells were demonstrated X100.	59
Fig.(46)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks stained with MTC. A mature collagen threads (arrows) were occupying the defect site in small number with a large number of active mature osteoblast cells were demonstrated and filling the defect site, X100.	60
Fig.(47)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks stained with MTC. Noted the bluish coloration bundles of arranged mature collagen (arrows) filling the defect site, X100.	60
Fig.(48)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks stained with MTC. Noted the dark bluish coloration bundles of arranged mature collagen (arrows) filling the defect site, X100.	61
Fig.(49)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks stained with MTC. An organized mature collagen was seen in arranged manner (arrows) with the presence of large number of active mature osteoblast cells, X100.	61
Fig.(50)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks stained with Alizarin red showing deposition of calcium (arrows) that appeared orange red in color within fibrous tissue at the ends of the defect site, X100.	62
Fig.(51)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks stained with Alizarin red. A large number of orange red coloration (arrows) that indicate the evidence of the presence of calcium deposition and pro-osteoblast cells were demonstrated, X100.	63
Fig.(52)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks stained with Alizarin red. Showing positive staining at the defect site (orange red coloration) with the presence of calcium	63

	deposition (arrows), X100.	
Fig.(53)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks stained with Alizarin red. Showing positive staining at the defect site (orange red coloration) with the presence of calcium deposition (arrows), X100.	64
Fig.(54)	Photomicrograph of the bone defect site in simvastatin group at 4 weeks, showing positive staining at the defect site (light brown coloration) with the osteoblast cell activation (arrows) (arrows).(Immune histo-chemistry; osteopontin), X400.	65
Fig.(55)	Photomicrograph of the bone defect site in simvastatin group at 8 weeks showing positive staining at the defect site which taking the deep brown coloration with the osteoblast activation (arrows) with few number of osteoclast cells.(Immune histo-chemistry; osteopontin), X400.	65
Fig.(56)	Photomicrograph of the bone defect site in simvastatin group at 12 weeks. Showing positive staining at the defect site (more deep brown coloration) with the osteoblast cell activation (arrows).(Immune histo-chemistry; osteopontin), X400.	66
Fig.(57)	A photomicrograph of the control group after 4 weeks following surgery, A. bone cavity showing highly vascular granulation tissue. B. small blood vessels, C. the operated gap. H&E, 100X.	68
Fig.(58)	A photomicrograph of the control group after 8 weeks following surgery, A. small blood vessels. B. the gap in-between the normal bone, C. immature fibrous tissue . H&E, 100X.	69
Fig.(59)	A photomicrograph of the control group after 12 weeks following surgery, A. fibrous tissue and minimal osteoid tissue with blood vessels. B. normal bone, C. inner layer, D. outer layer . H&E, 100X.	69

Introduction

A large segmental long bone defect constitutes a challenging problem in orthopedic surgery. Although bone tissue usually heals spontaneously, but in complicated conditions such as pathological fractures or those situations leading to large bone defects, the healing process fails (**Johnson, Austin and Breur, 1994**).

Numerous surgical techniques have been advocated, to enhance the healing and fill the bone defects. Among considerations are restoration of skeletal continuity with biologically and biomechanically sound bone; the early return to unrestricted limb function, minimal patient's compromise, and/or compliance throughout the course of the treatment without the need for specialized surgical skills and/or equipment. Therefore, the optimal reconstruction modality for large segmental defects in long bones has yet to be established (**Oryan, Alidadi and Moshiri, 2013**).

Different types of glycosaminoglycans, growth factors, stem cells, natural grafts (auto-, allo- or xenograft) and biologic- and synthetic- based tissue engineered scaffolds are some of the examples (**Oryan, et al., 2013**).

Mundy, Garrett, Harris , et al., 1999 who mentioned firstly tested the effects of more than 30.000 compounds on bone formation and found that the addition of statins, including simvastatin almost 50% increase new bone formation in rats through enhancing the expression of bone Morphogenetic Protein-2 (BMP-2) gene mRNA.

Statins are potent compound widely used for inhibiting hepatic cholesterol biosynthesis by blocking 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), a key enzyme in the cellular mevalonate pathway (**Goldstein and Brown, 1990**).

Subsequent promising clinical and experimental studies were done on the effect of simvastatin on bone formation with significant radiographic, mechanical, biochemical and histological differences in fracture healing. (**Nyan, Sato, Oda, et al., 2007; Skoglund and Aspenberg, 2007; Wang, Xu, Yang and Lv, 2007; Ayukawa, Yasukawa, Moriyama, et al., 2009; Liu, Wu and Sun, 2009**).